Stockreport

Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF TARRYTOWN, N.Y. and PARIS, April 27, 2020 /PRNewswire/ --Libtayo decreased the risk of death by 32.4% compared to chemotherapyRegeneron and Sanofi plan regulatory submis [Read more]